{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:10:29Z","timestamp":1783750229146,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T00:00:00Z","timestamp":1531440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T00:00:00Z","timestamp":1531440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1038\/s41386-018-0150-5","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T17:07:47Z","timestamp":1531328867000},"page":"324-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model"],"prefix":"10.1038","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6057-2527","authenticated-orcid":false,"given":"Christina","family":"Gross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwesha","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durgesh","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1183-0101","authenticated-orcid":false,"given":"Francesco","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela R.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay M.","family":"Schroeder-Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Krzeski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada A.","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Puckett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Klann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Bassell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,13]]},"reference":[{"key":"150_CR1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrneurol.2016.81","volume":"12","author":"PB Crino","year":"2016","unstructured":"Crino PB. The mTOR signalling cascade: paving new roads to cure neurological disease. Nat Rev Neurol. 2016;12:379\u201392.","journal-title":"Nat Rev Neurol"},{"key":"150_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.neuron.2014.09.034","volume":"84","author":"O Lipton Jonathan","year":"2014","unstructured":"Lipton Jonathan O, Sahin M. The neurology of mTOR. Neuron. 2014;84:275\u201391.","journal-title":"Neuron"},{"key":"150_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s13311-015-0355-9","volume":"12","author":"C Gross","year":"2015","unstructured":"Gross C, Hoffmann A, Bassell GJ, Berry-Kravis EM. Therapeutic strategies in fragile X syndrome: from bench to bedside and back. Neurotherapeutics. 2015;12:584\u2013608.","journal-title":"Neurotherapeutics"},{"key":"150_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nrn4001","volume":"16","author":"JD Richter","year":"2015","unstructured":"Richter JD, Bassell GJ, Klann E. Dysregulation and restoration of translational homeostasis in fragile X syndrome. Nat Rev Neurosci. 2015;16:595\u2013605.","journal-title":"Nat Rev Neurosci"},{"key":"150_CR5","doi-asserted-by":"publisher","first-page":"15758","DOI":"10.1073\/pnas.242377399","volume":"99","author":"M Qin","year":"2002","unstructured":"Qin M, Kang J, Smith CB. Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA. 2002;99:15758\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"key":"150_CR6","doi-asserted-by":"publisher","first-page":"17504","DOI":"10.1073\/pnas.0407533101","volume":"101","author":"IJ Weiler","year":"2004","unstructured":"Weiler IJ, Spangler CC, Klintsova AY, Grossman AW, Kim SH, Bertaina-Anglade V, et al. Fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses. Proc Natl Acad Sci USA. 2004;101:17504\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"150_CR7","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1523\/JNEUROSCI.0937-07.2007","volume":"27","author":"RS Muddashetty","year":"2007","unstructured":"Muddashetty RS, Kelic S, Gross C, Xu M, Bassell GJ. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J Neurosci. 2007;27:5338\u201348.","journal-title":"J Neurosci"},{"key":"150_CR8","doi-asserted-by":"publisher","first-page":"7746","DOI":"10.1073\/pnas.122205699","volume":"99","author":"KM Huber","year":"2002","unstructured":"Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of Fragile X mental retardation. Proc Natl Acad Sci USA. 2002;99:7746\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"150_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.tins.2004.04.009","volume":"27","author":"MF Bear","year":"2004","unstructured":"Bear MF, Huber KM, Warren ST. The mGluR theory of Fragile X mental retardation. Trends Neurosci. 2004;27:370\u20137.","journal-title":"Trends Neurosci"},{"key":"150_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.coph.2014.11.004","volume":"20C","author":"SH Scharf","year":"2015","unstructured":"Scharf SH, Jaeschke G, Wettstein JG, Lindemann L. Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome. Curr Opin Pharmacol. 2015;20C:124\u201334.","journal-title":"Curr Opin Pharmacol"},{"key":"150_CR11","doi-asserted-by":"publisher","first-page":"321ra325","DOI":"10.1126\/scitranslmed.aab4109","volume":"8","author":"E Berry-Kravis","year":"2016","unstructured":"Berry-Kravis E, Des Portes V, Hagerman R, Jacquemont S, Charles P, Visootsak J, et al. Mavoglurant in Fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials. Sci Transl Med. 2016;8:321ra325\u2013321ra325.","journal-title":"Sci Transl Med"},{"key":"150_CR12","doi-asserted-by":"crossref","unstructured":"Bhattacharya A, Mamcarz M, Mullins C, Choudhury A, Boyle RG, Smith DG, et al. Targeting translation control with p70 S6 kinase 1 inhibitors to reverse phenotypes in Fragile X syndrome mice. Neuropsychopharmacology. 2016;41:1991\u20132000.","DOI":"10.1038\/npp.2015.369"},{"key":"150_CR13","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nm.4335","volume":"23","author":"I Gantois","year":"2017","unstructured":"Gantois I, Khoutorsky A, Popic J, Aguilar-Valles A, Freemantle E, Cao R, et al. Metformin ameliorates core deficits in a mouse model of fragile X syndrome. Nat Med. 2017;23:674\u20137.","journal-title":"Nat Med"},{"key":"150_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0092-8674(01)00568-2","volume":"107","author":"V Brown","year":"2001","unstructured":"Brown V, Jin P, Ceman S, Darnell JC, O\u2019Donnell WT, Tenenbaum SA, et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell. 2001;107:477\u201387.","journal-title":"Cell"},{"key":"150_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cell.2011.06.013","volume":"146","author":"JC Darnell","year":"2011","unstructured":"Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011;146:247\u201361.","journal-title":"Cell"},{"key":"150_CR16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature11737","volume":"492","author":"M Ascano Jr.","year":"2012","unstructured":"Ascano M Jr., Mukherjee N, Bandaru P, Miller JB, Nusbaum JD, Corcoran DL, et al. FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature. 2012;492:382\u20136.","journal-title":"Nature"},{"key":"150_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0896-6273(03)00034-5","volume":"37","author":"KY Miyashiro","year":"2003","unstructured":"Miyashiro KY, Beckel-Mitchener A, Purk TP, Becker KG, Barret T, Liu L, et al. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron. 2003;37:417\u201331.","journal-title":"Neuron"},{"key":"150_CR18","doi-asserted-by":"publisher","first-page":"10624","DOI":"10.1523\/JNEUROSCI.0402-10.2010","volume":"30","author":"C Gross","year":"2010","unstructured":"Gross C, Nakamoto M, Yao X, Chan CB, Yim SY, Ye K, et al. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci. 2010;30:10624\u201338.","journal-title":"J Neurosci"},{"key":"150_CR19","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1523\/JNEUROSCI.3696-09.2010","volume":"30","author":"A Sharma","year":"2010","unstructured":"Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T, McBride SM, Klann E, et al. Dysregulation of mTOR signaling in Fragile X syndrome. J Neurosci. 2010;30:694\u2013702.","journal-title":"J Neurosci"},{"key":"150_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.celrep.2015.03.065","volume":"11","author":"C Gross","year":"2015","unstructured":"Gross C, Raj N, Molinaro G, Allen AG, Whyte AJ, Gibson JR, et al. Selective role of the catalytic PI3K subunit p110beta in impaired higher order cognition in Fragile X syndrome. Cell Rep. 2015;11:681\u20138.","journal-title":"Cell Rep"},{"key":"150_CR21","doi-asserted-by":"publisher","first-page":"729","DOI":"10.18632\/oncotarget.207","volume":"1","author":"HA Dbouk","year":"2010","unstructured":"Dbouk HA, Backer JM. A beta version of life: p110\u03b2 takes center stage. Oncotarget. 2010;1:729\u201333.","journal-title":"Oncotarget"},{"key":"150_CR22","first-page":"188","volume":"2","author":"B Li","year":"2014","unstructured":"Li B, Sun A, Jiang W, Thrasher JB, Terranova P. PI-3 kinase p110\u03b2: a therapeutic target in advanced prostate cancers. Am J Clin Exp Urol. 2014;2:188\u201398.","journal-title":"Am J Clin Exp Urol"},{"key":"150_CR23","unstructured":"Rivero RA, Tedesco R, Luengo JI. Benzimidazole boronic acid derivatives as PI3 kinase inhibitors. Google patents, 2014. https:\/\/www.google.com\/patents\/US8778937."},{"key":"150_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.neuron.2012.07.022","volume":"76","author":"A Bhattacharya","year":"2012","unstructured":"Bhattacharya A, Kaphzan H, Alvarez-Dieppa AC, Murphy JP, Pierre P, Klann E. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron. 2012;76:325\u201337.","journal-title":"Neuron"},{"key":"150_CR25","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/nprot.2006.170","volume":"1","author":"RM Deacon","year":"2006","unstructured":"Deacon RM. Assessing nest building in mice. Nat Protoc. 2006;1:1117\u20139.","journal-title":"Nat Protoc"},{"key":"150_CR26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.bbr.2011.04.049","volume":"223","author":"AM Thomas","year":"2011","unstructured":"Thomas AM, Bui N, Graham D, Perkins JR, Yuva-Paylor LA, Paylor R. Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome. Behav Brain Res. 2011;223:310\u201321.","journal-title":"Behav Brain Res"},{"key":"150_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-016-0077-9","volume":"7","author":"A Banerjee","year":"2016","unstructured":"Banerjee A, Luong JA, Ho A, Saib AO, Ploski JE. Overexpression of Homer1a in the basal and lateral amygdala impairs fear conditioning and induces an autism-like social impairment. Mol Autism. 2016;7:16.","journal-title":"Mol Autism"},{"key":"150_CR28","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nrn2851","volume":"11","author":"JL Silverman","year":"2010","unstructured":"Silverman JL, Yang M, Lord C, Crawley JN. Behavioural phenotyping assays for mouse models of autism. Nat Rev Neurosci. 2010;11:490\u2013502.","journal-title":"Nat Rev Neurosci"},{"key":"150_CR29","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1016\/j.bmcl.2012.01.092","volume":"22","author":"H Lin","year":"2012","unstructured":"Lin H, Erhard K, Hardwicke MA, Luengo JI, Mack JF, McSurdy-Freed J, et al. Synthesis and structure\u2013activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors. Bioorg Med Chem Lett. 2012;22:2230\u20134.","journal-title":"Bioorg Med Chem Lett"},{"key":"150_CR30","doi-asserted-by":"publisher","first-page":"H1022","DOI":"10.1152\/ajpheart.2000.279.3.H1022","volume":"279","author":"H Murakami","year":"2000","unstructured":"Murakami H, Takanaga H, Matsuo H, Ohtani H, Sawada Y. Comparison of blood\u2013brain barrier permeability in mice and rats using in situ brain perfusion technique. Am J Physiol Heart Circ Physiol. 2000;279:H1022\u201328.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"150_CR31","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1038\/sj.npp.1301641","volume":"33","author":"Y Dwivedi","year":"2008","unstructured":"Dwivedi Y, Rizavi HS, Teppen T, Zhang H, Mondal A, Roberts RC, et al. Lower phosphoinositide 3-kinase (PI 3-kinase) activity and differential expression levels of selective catalytic and regulatory PI 3-kinase subunit isoforms in prefrontal cortex and hippocampus of suicide subjects. Neuropsychopharmacology. 2008;33:2324\u201340.","journal-title":"Neuropsychopharmacology"},{"key":"150_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fnmol.2015.00075","volume":"8","author":"A Biever","year":"2015","unstructured":"Biever A, Valjent E, Puighermanal E. Ribosomal protein S6 phosphorylation in the nervous system: from regulation to function. Front Mol Neurosci. 2015;8:75.","journal-title":"Front Mol Neurosci"},{"key":"150_CR33","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1128\/MCB.24.8.3112-3124.2004","volume":"24","author":"M Pende","year":"2004","unstructured":"Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, et al. S6K1(\u2212\/\u2212)\/S6K2(\u2212\/\u2212) mice exhibit perinatal lethality and rapamycin-sensitive 5\u2032-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol. 2004;24:3112\u201324.","journal-title":"Mol Cell Biol"},{"key":"150_CR34","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nmeth.1314","volume":"6","author":"EK Schmidt","year":"2009","unstructured":"Schmidt EK, Clavarino G, Ceppi M, Pierre P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009;6:275\u20137.","journal-title":"Nat Methods"},{"key":"150_CR35","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1601-183X.2004.00087.x","volume":"3","author":"QJ Yan","year":"2004","unstructured":"Yan QJ, Asafo-Adjei PK, Arnold HM, Brown RE, Bauchwitz RP. A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes Brain Behav. 2004;3:337\u201359.","journal-title":"Genes Brain Behav"},{"key":"150_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.5582\/irdr.2014.01024","volume":"3","author":"TM Kazdoba","year":"2014","unstructured":"Kazdoba TM, Leach PT, Silverman JL, Crawley JN. Modeling fragile X syndrome in the Fmr1 knockout mouse. Intractable Rare Dis Res. 2014;3:118\u201333.","journal-title":"Intractable Rare Dis Res"},{"key":"150_CR37","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/nm.3353","volume":"19","author":"T Udagawa","year":"2013","unstructured":"Udagawa T, Farny NG, Jakovcevski M, Kaphzan H, Alarcon JM, Anilkumar S, et al. Genetic and acute CPEB1 depletion ameliorate fragile X pathophysiology. Nat Med. 2013;19:1473\u20137.","journal-title":"Nat Med"},{"key":"150_CR38","doi-asserted-by":"publisher","first-page":"336","DOI":"10.2119\/molmed.2011.00363","volume":"18","author":"C Gross","year":"2012","unstructured":"Gross C, Bassell GJ. Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110beta-selective inhibitor. Mol Med. 2012;18:336\u201345.","journal-title":"Mol Med"},{"key":"150_CR39","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuron.2008.05.023","volume":"59","author":"S Park","year":"2008","unstructured":"Park S, Park JM, Kim S, Kim JA, Shepherd JD, Smith-Hicks CL, et al. Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc\/Arg3.1 essential for mGluR-LTD. Neuron. 2008;59:70\u201383.","journal-title":"Neuron"},{"key":"150_CR40","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1016\/j.celrep.2015.11.013","volume":"13","author":"W Guo","year":"2015","unstructured":"Guo W, Ceolin L, Collins KA, Perroy J, Huber KM. Elevated CaMKIIalpha and hyperphosphorylation of homer mediate circuit dysfunction in a fragile X syndrome mouse model. Cell Rep. 2015;13:2297\u2013311.","journal-title":"Cell Rep"},{"key":"150_CR41","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nn.3033","volume":"15","author":"JA Ronesi","year":"2012","unstructured":"Ronesi JA, Collins KA, Hays SA, Tsai NP, Guo W, Birnbaum SG, et al. Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome. Nat Neurosci. 2012;15:431\u201340. S431","journal-title":"Nat Neurosci"},{"key":"150_CR42","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1126\/science.1151227","volume":"319","author":"GN Huang","year":"2008","unstructured":"Huang GN, Huso DL, Bouyain S, Tu J, McCorkell KA, May MJ, et al. NFAT binding and regulation of T cell activation by the cytoplasmic scaffolding Homer proteins. Science. 2008;319:476\u201381.","journal-title":"Science"},{"key":"150_CR43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrm2882","volume":"11","author":"B Vanhaesebroeck","year":"2010","unstructured":"Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11:329\u201341.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"150_CR44","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1111\/febs.12428","volume":"280","author":"GC Smith","year":"2013","unstructured":"Smith GC, Ong WK, Costa JL, Watson M, Cornish J, Grey A, et al. Extended treatment with selective phosphatidylinositol 3-kinase and mTOR inhibitors has effects on metabolism, growth, behaviour and bone strength. FEBS J. 2013;280:5337\u201349.","journal-title":"FEBS J"},{"key":"150_CR45","doi-asserted-by":"publisher","first-page":"12165","DOI":"10.1073\/pnas.1206118109","volume":"109","author":"AJ Law","year":"2012","unstructured":"Law AJ, Wang Y, Sei Y, O\u2019Donnell P, Piantadosi P, Papaleo F, et al. Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110delta inhibition as a potential therapeutic strategy. Proc Natl Acad Sci USA. 2012;109:12165\u201370.","journal-title":"Proc Natl Acad Sci USA"},{"key":"150_CR46","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/nn.2937","volume":"14","author":"JI Kim","year":"2011","unstructured":"Kim JI, Lee HR, Sim SE, Baek J, Yu NK, Choi JH, et al. PI3Kgamma is required for NMDA receptor-dependent long-term depression and behavioral flexibility. Nat Neurosci. 2011;14:1447\u201354.","journal-title":"Nat Neurosci"},{"key":"150_CR47","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.1523\/JNEUROSCI.4632-15.2016","volume":"36","author":"F Papaleo","year":"2016","unstructured":"Papaleo F, Yang F, Paterson C, Palumbo S, Carr GV, Wang Y, et al. Behavioral, Neurophysiological, and synaptic impairment in a transgenic neuregulin1 (NRG1-IV) murine schizophrenia model. J Neurosci. 2016;36:4859\u201375.","journal-title":"J Neurosci"},{"key":"150_CR48","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/jnci\/djt277","volume":"105","author":"R Pilarski","year":"2013","unstructured":"Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst. 2013;105:1607\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"150_CR49","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s13311-015-0359-5","volume":"12","author":"PE Davis","year":"2015","unstructured":"Davis PE, Peters JM, Krueger DA, Sahin M. Tuberous sclerosis: a new frontier in targeted treatment of autism. Neurotherapeutics. 2015;12:572\u201383.","journal-title":"Neurotherapeutics"},{"key":"150_CR50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.tig.2016.01.001","volume":"32","author":"JN Crawley","year":"2016","unstructured":"Crawley JN, Heyer W-D, LaSalle JM. Autism and cancer share risk genes, pathways, and drug targets. Trends Genet. 2016;32:139\u201346.","journal-title":"Trends Genet"}],"updated-by":[{"DOI":"10.1038\/s41386-022-01345-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000}}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-018-0150-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-018-0150-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-018-0150-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T16:39:47Z","timestamp":1655224787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-018-0150-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,13]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["150"],"URL":"https:\/\/doi.org\/10.1038\/s41386-018-0150-5","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41386-022-01345-x","asserted-by":"object"}]},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,13]]},"assertion":[{"value":"26 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41386-022-01345-x","URL":"https:\/\/doi.org\/10.1038\/s41386-022-01345-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GSK6A was obtained through a Material Transfer Agreement from GlaxoSmithKline. R.A.R. is an employee of GlaxoSmithKline, who owns GSK6A, and is co-inventor on US patents US 20130157977A1 and US 8778937B2. C.G. and G.J.B. are co-inventors on provisional patent application 62\/680,050. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}